Sabrina, welcome.
In your view, what are going to be the key trends shaping the
biopharmaceutical sector this year?
Do you think?
I think, number one, of course, GenAI
is everywhere.
Yeah.
So we'll have, we will see how the industry research and
development will be influenced.
We do see on the supply chain side, quite some developments
coming up on operations, on commercial side.
I think every pharma industry is testing the waters and to seize
how to create value with the technology.
Number one.
Number two, innovation, of course.
Yeah, question will be, I mean we have seen the GLP-1s hitting
the market.
Yeah, Alzheimer's in Europe is a big question mark.
EMA was quite skeptical in the beginning.
Right now we got green light.
So how will the market develop there for patients?
And then we have new technologies coming to market
like RLTs.
And in Europe, every market is so different.
Yeah.
So you have different regulatory requirements for how you're
setting up the clinical pathways, what you put in place
on infrastructure.
So I think there are many questions on the physician side
at the moment and I think pharmaceutical industry does a
great job in Europe to address them.
What are you most excited about at the moment?
You spoke about all those innovations.
Anything there?
I'm most excited about the performance of my clients.
We have amazing European-headquartered
pharmaceutical companies on the innovative side, but also on the
generic side, on pharmaceutical wholesale.
So I think the clients have realized that Europe is of
course a big region, but all the markets have their individual
kind of challenges, requirements, political environments.
And if I see how my clients have, top of their mind, how to
best serve the patients there, in light of all economic
challenges, that I think we will see increasingly across European
countries, that impresses me every day.
What do you think industry leaders, though, need to keep in mind?
What should be top priority?
Look, industry leaders, of course, many of the large
companies they're listed.
So stock price and how the market is evolving is of course
a question right now in a new economic environment.
Also with more pressure on budgets, more pressure on price.
Having on the US side, IRA coming into play, of course some
of them will see pressure on P&L side.
Many of them have already prepared.
Question will be about growth I think.
And if I look at the large players, they have amazing
pipelines and really broad portfolios, but what will really
drive growth in that industry?
Thank you so much for your time.
Thank you.